Drug Type Small molecule drug |
Synonyms TOP 1630, TOP1630 |
Mechanism LCK inhibitors(Tyrosine-protein kinase LCK inhibitors), SRC inhibitors(Tyrosine-protein kinase SRC inhibitors), Syk inhibitors(Spleen tyrosine kinase inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 3 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Dry Eye Syndromes | Phase 3 | US | 13 Feb 2019 | |
Dry Eye Syndromes | Phase 3 | US | 13 Feb 2019 | |
Xerophthalmia | Phase 3 | - | - |
Phase 2 | 69 | (Active) | hhdpfwnwvh(ntnrkecpeg) = ycxtgbdstx fnidbxtwob (bmuwucnfoi, onisetcmva - bthvlkylio) View more | - | 14 Feb 2024 | ||
Placebo to TOP1630 Ophthalmic Solution (Placebo) | hhdpfwnwvh(ntnrkecpeg) = cvphzzveqo fnidbxtwob (bmuwucnfoi, vhbbmdiqgg - bzcpdlwmed) View more | ||||||
NCT03088605 (Pubmed) Manual | Phase 2 | 61 | orgrcwcive(rmgicdbdmt): P-Value = <0.05 View more | Positive | 12 Feb 2019 | ||
Placebo |